Caplin Point Laboratories
Market Cap
₹39.7b
Last Updated
2020/10/27 12:50 UTC
Data Sources
Company Financials +
Executive Summary
Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally. More Details
Snowflake Analysis
Excellent balance sheet with proven track record.
Similar Companies
Share Price & News
How has Caplin Point Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 524742's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-2.1%
524742
-1.7%
IN Pharmaceuticals
-0.6%
IN Market
1 Year Return
34.3%
524742
45.4%
IN Pharmaceuticals
0.9%
IN Market
Return vs Industry: 524742 underperformed the Indian Pharmaceuticals industry which returned 45.4% over the past year.
Return vs Market: 524742 exceeded the Indian Market which returned 0.9% over the past year.
Shareholder returns
| 524742 | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.1% | -1.7% | -0.6% |
| 30 Day | -6.0% | -0.8% | 4.0% |
| 90 Day | 28.6% | 11.7% | 5.7% |
| 1 Year | 35.2%34.3% | 47.2%45.4% | 2.6%0.9% |
| 3 Year | -21.5%-22.8% | 22.6%19.3% | -2.8%-7.4% |
| 5 Year | 112.2%107.1% | -0.2%-3.7% | 39.9%29.5% |
Price Volatility Vs. Market
How volatile is Caplin Point Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Caplin Point Laboratories undervalued compared to its fair value and its price relative to the market?
17.88x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 524742 (₹518.35) is trading above our estimate of fair value (₹348.01)
Significantly Below Fair Value: 524742 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 524742 is good value based on its PE Ratio (17.9x) compared to the IN Pharmaceuticals industry average (22.8x).
PE vs Market: 524742 is poor value based on its PE Ratio (17.9x) compared to the Indian market (16.2x).
Price to Earnings Growth Ratio
PEG Ratio: 524742 is good value based on its PEG Ratio (0.9x)
Price to Book Ratio
PB vs Industry: 524742 is overvalued based on its PB Ratio (4.1x) compared to the IN Pharmaceuticals industry average (2.2x).
Next Steps
Future Growth
How is Caplin Point Laboratories forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
18.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 524742's forecast earnings growth (18.9% per year) is above the savings rate (7.2%).
Earnings vs Market: 524742's earnings (18.9% per year) are forecast to grow slower than the Indian market (25.6% per year).
High Growth Earnings: 524742's earnings are forecast to grow, but not significantly.
Revenue vs Market: 524742's revenue (16.4% per year) is forecast to grow faster than the Indian market (11.3% per year).
High Growth Revenue: 524742's revenue (16.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 524742's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Caplin Point Laboratories performed over the past 5 years?
30.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524742 has high quality earnings.
Growing Profit Margin: 524742's current net profit margins (24.1%) are lower than last year (27.2%).
Past Earnings Growth Analysis
Earnings Trend: 524742's earnings have grown significantly by 30% per year over the past 5 years.
Accelerating Growth: 524742's earnings growth over the past year (15.7%) is below its 5-year average (30% per year).
Earnings vs Industry: 524742 earnings growth over the past year (15.7%) exceeded the Pharmaceuticals industry 14.7%.
Return on Equity
High ROE: 524742's Return on Equity (23%) is considered high.
Next Steps
Financial Health
How is Caplin Point Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 524742's short term assets (₹8.2B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: 524742's short term assets (₹8.2B) exceed its long term liabilities (₹248.6M).
Debt to Equity History and Analysis
Debt Level: 524742's debt to equity ratio (3.8%) is considered satisfactory.
Reducing Debt: 524742's debt to equity ratio has increased from 2.2% to 3.8% over the past 5 years.
Debt Coverage: 524742's debt is well covered by operating cash flow (122.5%).
Interest Coverage: 524742's interest payments on its debt are well covered by EBIT (281.9x coverage).
Balance Sheet
Next Steps
Dividend
What is Caplin Point Laboratories's current dividend yield, its reliability and sustainability?
0.48%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 524742's dividend (0.48%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.56%).
High Dividend: 524742's dividend (0.48%) is low compared to the top 25% of dividend payers in the Indian market (2.29%).
Stability and Growth of Payments
Stable Dividend: 524742's dividends per share have been stable in the past 10 years.
Growing Dividend: 524742's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (8.6%), 524742's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.6yrs
Average management tenure
CEO
Sridhar Ganesan (65 yo)
5.58yrs
Tenure
₹5,686,000
Compensation
Dr. Sridhar Ganesan has been the Managing Director of Caplin Point Laboratories Ltd since March 28, 2015. Dr. Ganesan has been Whole Time Director of Caplin Point Laboratories Ltd since August 25, 2014. Dr ...
CEO Compensation Analysis
Compensation vs Market: Sridhar's total compensation ($USD76.90K) is below average for companies of similar size in the Indian market ($USD353.89K).
Compensation vs Earnings: Sridhar's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Whole Time Director | 5.58yrs | ₹5.69m | 0.11% ₹ 42.1m | |
| Chief Financial Officer | 4.67yrs | ₹3.83m | no data | |
| Company Secretary & Compliance Officer | no data | ₹944.00k | no data | |
| Chief Operating Officer | 9.17yrs | ₹1.82m | 11.9% ₹ 4.7b | |
| Head of Formulation & Development -Injectibles | no data | no data | no data | |
| Deputy Chief Financial Officer | no data | no data | no data |
5.6yrs
Average Tenure
Experienced Management: 524742's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Whole Time Director | 5.58yrs | ₹5.69m | 0.11% ₹ 42.1m | |
| Non-Executive Independent Director | 26.33yrs | ₹160.00k | 0.32% ₹ 126.7m | |
| Non-Executive Non-Independent Director | 12.75yrs | ₹60.00k | no data | |
| Non-Executive Chairman | no data | no data | 18.73% ₹ 7.4b | |
| Non-Executive Independent Director | 6.42yrs | ₹240.00k | no data | |
| Non-Executive Independent Director | 6.17yrs | ₹140.00k | no data | |
| Non-Executive Independent Director | 5.42yrs | ₹80.00k | no data | |
| Non-Executive Independent Director | 3.92yrs | ₹100.00k | no data | |
| Additional Non-Executive Independent Director | 0.58yr | no data | no data |
6.3yrs
Average Tenure
68yo
Average Age
Experienced Board: 524742's board of directors are considered experienced (6.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Caplin Point Laboratories Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Caplin Point Laboratories Limited
- Ticker: 524742
- Exchange: BSE
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹39.652b
- Shares outstanding: 75.64m
- Website: https://www.caplinpoint.net
Number of Employees
Location
- Caplin Point Laboratories Limited
- Ashvich Tower
- 3rd Floor
- Chennai
- Tamil Nadu
- 600096
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 524742 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Feb 2002 |
| CAPLIPOINT | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Feb 2002 |
Biography
Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally. It provides tablets, capsules, ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/27 12:50 |
| End of Day Share Price | 2020/10/27 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.